Sanofi joins J&J, Eli Lilly in proposing 340B rebate model Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs ...

Sanofi sues HHS to defend 340B rebate policy The drugmaker has joined Johnson & Johnson and Eli Lilly in filing suit against the Biden administration over controversial reform to the drug discount ...

"Sanofi challenges HRSA's decision to remove them from 340B Program over proposed credit model. Legal action follows pattern of pharmaceutical companies contest ...

Sanofi, Johnson & Johnson, Eli Lilly and Bristol Myers Squibb have each filed complaints after facing federal opposition to their 340B rebate proposals.

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

Sanofi is the latest drug company to sue HHS over payment terms for 340B hospitals The move came after the government threatened to sanction the company if it proceeded with its plans ...

Community health centers, which make up a smaller percentage than hospital systems of the 340B program, will receive credits faster but still need to send Sanofi claims data, according to the letter.

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the 340B program.

Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to "buy low and sell high" by purchasing discounted medications and charging insured ...

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide pharmacy and medical claims information before ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...